Controlled document PF-019A
KORR Master Formula
Record identification
- Document ID
- PF-019A
- Document type
- Template
- Status
- Documented
- Source
- Standardisation & Production of SIRIAM Products
Overview
PF-019A
PRODUCT FORMULA CARD
SIRIAM KORR – BASELINE NEURODERMAL RESET
DOCUMENT CONTROL
Field
Product ID
Formula ID
Document
Product
Anatomical Region
Therapeutic Phase
Product Type
Standard Batch
Version
Status
Internal QR
| Value |
|---|
| SIR-KORR-001 |
| MF-019 |
| PF-019A |
| KORR |
| C2–S2 |
| Baseline Neurodermal Reset |
| Topical Magistral Cream |
| 100 g |
| 2.0 |
| 🔒 LOCKED |
| ☐ |
1. PRODUCT PURPOSE
Field
Clinical Objective
Anatomical Region
Primary Biological Target
Therapeutic Phase
Product Type
This purpose follows the magistral fiche, which defines KORR as a baseline neurodermal modulator for facilitated segments from C2 to S2 without a directional stimulus.
| Description |
|---|
| Baseline neurodermal modulation of facilitated spinal segments |
| C2–S2 |
| Normalisation of afferent input, resting tone and EMG response without directional stimulation |
| Baseline Neurodermal Reset |
| Topical Magistral Cream |
2. MASTER FORMULA
The master formula is based on the uploaded KORR magistral fiche, with the agreed SQMS standardisation of Vitamin E Full Spectrum and Silicea Gel (+1 drop Silicea D8). The source also notes that Aqua Purificata may be increased to 22–24 g to improve MSM and magnesium dissolution; this is retained as a development consideration rather than changing the validated master formula.
| Code |
|---|
| Official Ingredient |
| Current |
| Proposed |
| Unit |
| PC-001 |
| Lanette Cream FNA |
| 65.00 |
| g |
| PC-002 |
| Aqua Purificata |
| 20.00 |
| g |
| SC-002 |
| MSM |
| 5.00 |
| g |
| SC-001 |
| Magnesium Chloride |
| 3.00 |
| g |
| OC-002 |
| Jojoba Oil |
| 10.00 |
| g |
| SC-003 |
| D-Panthenol |
| 0.50 |
| g |
| SC-004 |
| Vitamin E Full Spectrum |
| 0.50 |
| g |
| BE-007 |
| Rhodiola rosea |
| 1.00 |
| g |
| BE-015 |
| Calendula officinalis Tincture |
| 1.00 |
| g |
| SC-005 |
| Silicea Gel (+1 drop Silicea D8) |
| 1.00 |
| g |
| PR-001 |
| Cosgard 221 |
| 0.70 |
| g |
3. MANUFACTURING WORKFLOW
Step
1
2
3
4
5
6
7
8
9
10
11
This workflow follows the Lanette preparation protocol in the magistral fiche.
| Action |
|---|
| ✓ |
| Verify raw materials |
| □ |
| Prepare water phase |
| □ |
| Completely dissolve MSM and Magnesium Chloride |
| □ |
| Emulsify Lanette base |
| □ |
| Cool below 40°C |
| □ |
| Add Rhodiola and Calendula |
| □ |
| Add Silicea Gel (+1 drop Silicea D8) |
| □ |
| Cool below 35°C and add thermolabile ingredients |
| □ |
| Quality Control |
| □ |
| Fill into 15 mL airless dispensers |
| □ |
| Batch Release |
| □ |
4. QUALITY CONTROL
Standard SQMS Quality Control
Parameter
Appearance
Colour
Odour
Homogeneity
pH
Viscosity
Packaging
Net Weight
| Target |
|---|
| Result |
| Standard |
| Standard |
| Standard |
| Pass |
| 5.2–5.5 |
| Airless compatible |
| Pass |
| Pass |
5. BATCH RELEASE
Standard SQMS Batch Release
6. CLINICAL APPLICATION
Field
Anatomical Region
Primary Zone
Frequency
Primary Indication
Secondary Indication
Clinical Integration
Functional Validation
The application instructions recommend use on the selected segment between C2 and S2 and integration with SRST and EMG evaluation.
⭐ One recommendation for Handbook v1.0
I would not classify KORR as a DUO product.
Instead, in the handbook structure:
DUO Products
OAA
PHRENIC
CTO
Solaris
Plexus Brachialis
TLO
Plexus Lumbalis
Plexus Lumbosacralis
SX
and then a separate category:
Core System Products
KORR (Baseline Neurodermal Reset)
This reflects its actual role: KORR is not a Release/Integration sequence but the universal baseline formulation that can be used before, between or independently of the DUO systems. I think that distinction will make the handbook clearer and will also translate very naturally into the future Lovable product architecture.
| Value |
|---|
| C2–S2 |
| Selected facilitated spinal segment |
| 1–2× daily |
| Baseline neurodermal reset |
| Maintenance therapy |
| Combine with SRST assessment |
| EMG before and after application |
Related documents
Platform modules